share_log

Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target

Benzinga ·  Apr 17 20:49

Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment